Investigation Concerning Combined Use of Acidophilus Biologics and Antibiotics or Anticancer Drugs

DOI 13 References
  • Fushitani Shuji
    Department of Pharmacy,Tokushima University Hospital
  • Shibata Hirohumi
    Department of Molecular Cell Biology and Medicine,Institute of Health Biosciences,the University of Tokushima Graduate School
  • Teraoka Kazuhiko
    Department of Pharmacy,Tokushima University Hospital
  • Nakamura Toshimi
    Department of Pharmacy,Tokushima University Hospital
  • Nishisako Hirotaka
    Department of Pharmacy,Tokushima University Hospital
  • Kawazoe Kazuyoshi
    Department of Pharmacy,Tokushima University Hospital Department of Clinical Pharmacy,Institute of Health Biosciences,the University of Tokushima Graduate School
  • Minakuchi Kazuo
    Department of Pharmacy,Tokushima University Hospital Department of Clinical Pharmacy,Institute of Health Biosciences,the University of Tokushima Graduate School

Bibliographic Information

Other Title
  • 抗菌薬，抗がん剤による薬物療法における乳酸菌生菌製剤の併用状況

Search this article

Description

Diarrhea is a very common,important adverse effect associated with antibiotic therapy.For the prevention and treatment of diarrhea,Biofermin (BF) probiotic preparations are prescribed frequently and an antibiotic-resistant probiotic BioferminR (BFR) is particularly useful against antibiotic-associated diarrhea.BFR is often prescribed in combination with antibiotics to which the probiotic is susceptible or with off-label drugs such as anti-cancer drugs.<br>We investigated the concurrent usage of such probiotics and antibiotics and anti-cancer drugs using data from the database of a computer order entry system at the Tokushima University Hospital (April 2006 to March 2008),as well through the use of a questionnaire given to hospital doctors.The results of our study suggested that not all doctors had a sufficient knowledge of the usage of BFR when prescribing it.In routine pharmacy work,pharmacists should therefore actively question doctors concerning prescriptions they have written for the combination of BFR and off-label drugs to ensure the proper use of BFR and prevent the emergence of drug-resistant bacteria due to bacterial mutagenicity associated with antibiotics and anti-cancer drugs.

Journal

References(13)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top